New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial

Acta Diabetologica

Volumn 41, Issue SUPPL. 1, 2004, Pages

  Laville, M ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Anaemia; Cardiovascular disease; Chronic kidney disease; Diabetes; End stage renal disease; Epoetin

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; EPOETIN ALFA; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1642393914     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00592-004-0134-2     Document Type: Conference Paper

References (26)

1. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]:S112-S119
2. Foley RN, Parfrey PS, Harnett JD et al (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192
3. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890
4. Parfrey PS, Harnett JD, Foley RN (1995) Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hyperten 4:105-110
5. Foley RN, Culleton BF, Parfrey PS et al (1997) Cardiac disease in diabetic end-stage renal disease. Diabetologia 40:1307-1312
6. Ma JZ, Ebben J, Xia H, Collins AJ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619
7. Arkouche W, Traeger J, Delawari E et al (1999) Twenty-five years of experience with out-center hemodialysis. Kidney Int 56:2269-2275
8. - (2000) US Renal Data System, USRDS 2000 annual data report: atlas of end-stage renal disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda
9. Parving HH (2001) Diabetic nephropathy: prevention and treatment. Kidney Int 60:2041-2055
10. Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 68:85-89
11. American Diabetes Association (1999) Management of dyslipidemia in adults with diabetes. Diabetes Care 22[Suppl 1]:S56-S59
12. Levin A, Thompson CR, Ethier J et al (1999) Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134
13. Holland DC, Lam M (2000) Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 15:650-658
14. Locatelli F, Conte F, Marcelli D (1998) The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13:1642-1644
15. - (1999) European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14[Suppl 5]:1-50
16. - (2001) NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000 Am J Kidney Dis 37[Suppl 1]:S182-S238
17. Fink JC, Blahut SA, Reddy M, Light PD (2001) Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355
18. Xue JL, Ebben JP, St Peter WL, Constantini EG, Collins AJ (2001) Correction of anemia with erythropoietin during the two-year pre-ESRD period: post-ESRD mortality. J Am Soc Nephrol 12:259A (abstract)
19. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185
20. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK (2001) Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312
21. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A (1997) Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548
22. Hayashi T, Suzuki A, Shoji T et al (2000) Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256
23. Valderrabano F, on behalf of the Spanish Group for the Study of the Anaemia and Left Ventricular Hypertrophy in Predialysis Patients (2000) Improvement and prevention of left ventricular hypertrophy in predialysis patients. J Am Soc Nephrol 11:A0424 (abstract)
24. Rarick MU, Espina BM, Colley DT, Chrusoskie A, Gandara S, Feinstein DI (1998) Treatment of a unique anemia in patients with IDDM with epoetin alfa. Diabetes Care 21:423-426
25. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ (1999) Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 16:813-819
26. Thomas S, Rampersad M (2004) Anaemia in diabetes. Acta Diabetol 41[Suppl 1]:S13-S17